Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipratropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.98 |
| ▸ | TSHR | P16473 | 2/20 | 0.93 |
| ▸ | BLM | P54132 | 3/20 | 0.77 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipratropium SCHEMBL22077027 | 0.99 | CHRM2 (1.00) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL1476940 | 0.99 | CHRM2 (1.00) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL17271494 | 0.99 | CHRM2 (0.96) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL1476937 | 0.99 | CHRM2 (1.00) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL99102 | 0.99 | CHRM2 (0.96) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL820105 | 0.99 | CHRM2 (1.00) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL8442770 | 0.99 | CHRM2 (0.96) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL22077028 | 0.99 | CHRM2 (0.96) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL28500928 | 0.98 | CHRM2 (0.94) | CHRM2CHRM5CHRM4CHRM1CHRM3 | |
| Ipratropium SCHEMBL29152427 | 0.98 | CHRM2 (0.98) | CHRM2CHRM5CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077140-A1 | METERED DOSE INHALER FOR IPRATROPIUM BROMIDE SOLUTION | GLENMARK PHARMACEUTICALS LTD (IN) | 2026-03-19 | — | — | US | claimed |
| US-12502489-B1 | Metered dose inhaler for ipratropium bromide solution | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2025-12-23 | — | — | US | claimed |
| EP-3624771-B1 | METHOD OF MAINTAINING A WATER LEVEL IN A PRESSURIZED AEROSOL CANISTER. | KINDEVA DRUG DELIVERY LP (US) | 2023-11-15 | — | — | EP | claimed |
| CN-113820404-B | UPLC analysis method of ipratropium bromide aerosol | 山东达因海洋生物制药股份有限公司 | 2023-04-25 | — | — | CN | claimed |
| CN-113943286-B | Preparation method of choline receptor antagonist | 上海方予健康医药科技有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-112438966-B | Medical quantitative inhalation aerosol | 四川普锐特药业有限公司 | 2022-08-26 | — | — | CN | claimed |
| EP-1809243-B2 | AEROSOL SUSPENSION FORMULATIONS CONTAINING TG 227 EA AS A PROPELLANT | BOEHRINGER INGELHEIM INT (DE) | 2022-06-08 | — | — | EP | claimed |
| CN-110845492-B | Ipratropium bromide monohydrate | 鲁南制药集团股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| US-20220040086-A1 | FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2022-02-10 | — | — | US | claimed |
| CN-113943286-A | Preparation method of choline receptor antagonist | 上海方予健康医药科技有限公司 | 2022-01-18 | — | — | CN | claimed |
| EP-1608336-B1 | FORMULATION FOR A METERED DOSE INHALER USING HYDRO-FLUORO-ALKANES AS PROPELLANTS | BOEHRINGER INGELHEIM PHARMA (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070183982-A1 | Pharmaceutical composition for aerosols with two or more active substances and at least one surfactant | BERKEL ERHARD | 2007-08-09 | — | — | US | claimed |
| CN-1984642-A | Aerosol suspension formulations containing TG 227 ea or TG 134 a as a propellant | BOEHRINGER INGELHEIM INT (DE) | 2007-06-20 | — | — | CN | claimed |
| US-20070041911-A1 | HFC SOLUTION FORMULATIONS CONTAINING SALBUTAMOL HYDROCHLORIDE OR SALBUTAMOL CITRATE | SCHMIDT FRIEDRICH | 2007-02-22 | — | — | US | claimed |
| US-6983743-B2 | Stainless steel canister for propellant-driven metering aerosols | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2006-01-10 | — | — | US | claimed |
| US-20060002863-A1 | Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-05 | — | — | US | claimed |
| EP-1608336-A2 | FORMULATION FOR A METERED DOSE INHALER USING HYDRO-FLUORO-ALKANES AS PROPELLANTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-12-28 | — | — | EP | claimed |
| US-20040211411-A1 | Stainless steel canister for propellant-driven metering aerosols | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-10-28 | — | — | US | claimed |
| WO-2004084858-A2 | FORMULATION FOR A METERED DOSE INHALER USING HYDRO-FLUORO-ALKANES AS PROPELLANTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-10-07 | — | — | WO | claimed |
| US-20040184994-A1 | Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220040086-A1 | FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION | MCOLN3, SYMPK, ADRB2 | CHRM3 20/4885CHRM2 47/4885CHRM5 30/4885 |
| US-20260077140-A1 | METERED DOSE INHALER FOR IPRATROPIUM BROMIDE SOLUTION | ADRB2, CHRM2, CHRNB1 | CHRM3 5/4885CHRM2 2/4885CHRM5 8/4885 |
| US-20070041911-A1 | HFC SOLUTION FORMULATIONS CONTAINING SALBUTAMOL HYDROCHLORIDE OR SALBUTAMOL CITRATE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MYOC, OTC | CHRM3 17/4885CHRM2 154/4885CHRM5 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.